Therapy-related myeloid leukemia
Citation, DOI and article data
Therapy-related myeloid leukaemias, also referred to as therapy-related myeloid neoplasms, occur as a late complication after cytotoxic therapies (e.g. chemotherapy, immunosuppressive therapy, and radiation therapy) performed to treat other conditions. They represent hematological malignancies where a causal relationship has been implied, and have been recognized as distinct entities by the WHO classification of tumors of hematopoietic and lymphoid tissues.
- therapy-related acute myeloid leukemia (t-AML)
- therapy-related myelodysplastic syndrome (t-MDS)
- therapy-related myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPN)
They are known to have poor outcomes compared to the de novo cases of these entities. For further discussion, please refer to the main articles of each myeloid neoplasm.
- 1. Godley LA, Larson RA. Therapy-related myeloid leukemia. (2008) Seminars in oncology. 35 (4): 418-29. doi:10.1053/j.seminoncol.2008.04.012 - Pubmed
- 2. Sabine Kayser, Konstanze Döhner, Jürgen Krauter, Claus-Henning Köhne, Heinz A. Horst, Gerhard Held, Marie von Lilienfeld-Toal, Sibylla Wilhelm, Andrea Kündgen, Katharina Götze, Mathias Rummel, David Nachbaur, Brigitte Schlegelberger, Gudrun Göhring, Daniela Späth, Carina Morlok, Manuela Zucknick, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk, for the German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. (2011) Blood. 117 (7): 2137. doi:10.1182/blood-2010-08-301713 - Pubmed